Warren Street Wealth Advisors LLC Purchases 100 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Warren Street Wealth Advisors LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 609 shares of the pharmaceutical company’s stock after purchasing an additional 100 shares during the quarter. Warren Street Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $271,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals in the 1st quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. Flaharty Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at $32,000. American National Bank & Trust boosted its stake in shares of Vertex Pharmaceuticals by 515.4% in the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after purchasing an additional 67 shares in the last quarter. Finally, SJS Investment Consulting Inc. boosted its stake in shares of Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VRTX. Guggenheim cut their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 5th. Leerink Partners raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price objective for the company from $458.00 to $456.00 in a research note on Thursday, September 25th. Raymond James Financial started coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. Finally, Royal Bank Of Canada lowered their price target on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $493.81.

Vertex Pharmaceuticals Trading Up 3.2%

Shares of NASDAQ VRTX opened at $404.21 on Thursday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a market capitalization of $103.64 billion, a PE ratio of 28.89 and a beta of 0.43. The firm has a fifty day simple moving average of $401.71 and a two-hundred day simple moving average of $444.45.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the business earned ($12.83) EPS. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.